Log in to your Inderes Free account to see all free content on this page.
Q-Linea
3.565 SEK -0.83%1 investor is following this company
Q-Linea is active in medical technology. The company specializes in the research and development of instruments and consumables. The products are mainly used in the treatment of infectious diseases and blood poisoning and include diagnostic and analysis tools, as well as other related basic sample handlings. The technology is based on the so-called ID and AST technology. The company was founded in 2008 and is headquartered in Uppsala.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
QLINEA
Daily low / high price
3.445 / 3.695
SEK
Market cap
417.7M SEK
Turnover
390.79K SEK
Volume
109K
Latest videos
Financial calendar
Interim report
31.10.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Nexttobe AB | 53.5 % | 53.5 % |
Fjärde AP-fonden | 8.0 % | 8.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
![Q-Linea, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/97f28477-7d54-4d91-a7b5-55f65631d866.png)
Q-Linea, Audiocast with teleconference, Q2'24
Interim report 1 January - 30 June 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Invitation to presentation of Q-linea’s Interim report Q2-2024 on July 11, 2024
Q-linea participates in first public tender in Belgium
BULLETIN FROM ANNUAL GENERAL MEETING IN Q-LINEA AB (PUBL)
Q-linea announces shipment of first IVD-marked ASTar® instrument to the US
Q-linea receives another commercial order in Italy
CMS proposes to approve the ASTar system for NTAP funding
Redeye: Q-linea Update - Commercial progress and financial challenges
![Q-Linea, Audiocast with teleconference, Q1'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/e211690f-4e6e-4f62-a2b6-b0f4b769e8ac.png)